Karyopharm Therapeutics
KPTI
153 hedge funds and large institutions have $608M invested in Karyopharm Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 54 increasing their positions, 56 reducing their positions, and 38 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 5.37% → 5.24% (-0.14%)
4% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 56
5% less capital invested
Capital invested by funds: $637M → $608M (-$28.8M)
11% less funds holding
Funds holding: 171 → 153 (-18)
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
67% less call options, than puts
Call options by funds: $4.62M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$41.2M |
| 2 |
BlackRock
New York
|
+$9.98M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$5.29M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.69M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.8M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$8.9M |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$8.73M |
| 5 |
Two Sigma Investments
New York
|
-$6.26M |
KPTI Hedge Fund Activity: Q2 2021 in Review
153 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2021, worth a combined $608M — down 4.5% from $637M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of KPTI and 21 opened new positions — a net loss of 17 holders — while 56 trimmed existing stakes and 54 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $41.2M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $14.2M sold.
- 153 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2021, down from 171 in Q1 2021.
- Funds reported $608M of Karyopharm Therapeutics stock for Q2 2021, down 4.5% quarter-over-quarter.
- 21 funds opened new Karyopharm Therapeutics positions in Q2 2021 and 38 closed out, a net change of -17 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $41.2M added.
- The largest Karyopharm Therapeutics seller in Q2 2021 was Adage Capital Partners, an estimated $14.2M sold.
Based on aggregated 13F filings for Q2 2021.